Phase 3 Atrial Fibrillation Trial, Recruiting NCT05357690 Sponsor: Mayo Clinic Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 3 Atrial Fibrillation Trial, Recruiting

NCT05357690
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled for cardiac surgery at the Mayo Clinic in Rochester, Minnesota.
  • People who are scheduled to have mitral or aortic valve surgery, with or without also having coronary artery bypass grafting (a procedure to improve blood flow to the heart).

Who may not be able to join:

  • People who have a history of permanent atrial fibrillation (a long-term irregular heart rhythm condition), or who have had a heart assist device implanted or removed.
  • People whose planned surgery does not require the use of a heart-lung bypass machine during the procedure.
  • People whose planned surgery requires a technique involving cooling the body to very low temperatures to temporarily stop circulation.
  • People who currently have an active infection or sepsis (a serious, body-wide response to infection).
  • People who are taking immunosuppressive medications (drugs that reduce the immune system's activity) before surgery, including steroids.
  • People who are taking anti-arrhythmic medications (drugs to control irregular heart rhythms) before surgery, with the exception of beta-blockers.
  • People who have an immunodeficiency syndrome (a condition where the immune system does not work properly).
  • People who have a known neurological disorder (a condition affecting the brain or nervous system).
  • People who require a central line (a type of intravenous line) placed in the left internal jugular vein in the neck.
  • Note: People who have had a Maze procedure or left atrial appendage ligation are not automatically excluded from the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
19 April 2023
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of atrial fibrillation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov